Navigation Links
Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
Date:6/16/2008

tudy of Voreloxin and Cytarabine Indicates Activity of Combination Regimen

Preliminary results were also presented today from Sunesis' ongoing dose-escalating Phase 1b clinical trial evaluating voreloxin in combination with cytarabine, the current standard of care in patients with relapsed and/or refractory AML. The Phase 1b trial is designed to evaluate the safety and tolerability, and to provide a preliminary assessment of anti-leukemic activity, of escalating doses of voreloxin when administered on days one and four with a fixed dose of 400 mg/m2/day of cytarabine given as a continuous infusion for five days. Of twelve evaluable patients in the first three cohorts, three patients have achieved CRs (one at 20 mg/m2 of voreloxin and two at 34 mg/m2 of voreloxin). Six patients were enrolled in cohort 4 (50 mg/m2 of voreloxin), and no dose limiting toxicities have been observed thus far at this dose. Patients are now being enrolled in cohort 5 at 70 mg/m2 of voreloxin. Voreloxin pharmacokinetics have so far been unaffected by the combination with cytarabine.

"We are very pleased by the interim results reported today from our Phase 1b combination study of voreloxin with cytarabine. We look forward to reporting results from this study later in the year, including CR rates at 50 mg/m2 and higher dose levels of voreloxin," continued Dr. Michelson.

These data were presented today in a poster titled "Safety and Efficacy Experience of Voreloxin (formerly SNS-595) in Relapsed/Refractory Acute Leukemia Patients >/= 60 Years Old Compared to <60 Years Old: Results of a Phase 1b Study" (Abstract #0515) at the 13th Congress of the European Hematology Association. A copy of the poster will be available on the Sunesis corporate website at http://www.sunesis.com.

About Voreloxin (formerly SNS-595)

Sunesis' lead compound, voreloxin (formerly SNS-595), is a novel naphthyridine analog, structurally re
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
2. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
3. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
4. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
5. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
9. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
10. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
11. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)...  A recently published clinical study conducted at TOPS ... , demonstrates that 3D mammography (breast tomosynthesis) significantly reduces ... The study, "Implementation of Breast Tomosynthesis in a ... Stephen L. Rose , MD, and ... Journal of Roentgenology (AJR). The AJR is the ...
(Date:5/23/2013)... May 23, 2013  Hadasit Bio-Holdings Ltd. (TASE: HDST, ... companies, based on intellectual property developed and owned ... ,s foremost medical research center, today announced that ... significant funding from the Israeli Ministry of Industry ... to support product development and advance clinical trials. ...
(Date:5/23/2013)... , May 23, 2013  The need ... cancer treatment continuum was highlighted prominently at the ... Urological Association (AUA), in San Diego.  According to ... intensity focused ultrasound (HIFU) technology, the need for ... and for urologists to consider minimally invasive ablative ...
Breaking Medicine Technology:First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 2First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 3Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 2Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 3Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 4Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 5Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 6
... 17, 2012  Amy Langan, Vice President of Marketing and ... its enhanced labeling for sterile intravenous compounded ... Critical Care Exposition, May 19-24, 2012 in Orlando, Florida. ... Langan invites critical care professionals to visit Booth #2668 ...
... FRANCISCO, May 17, 2012  Varian Medical Systems (NYSE: ... early-stage inoperable lung cancer and other conditions non-invasively at ... (ATS) later this week in San Francisco.  ... of pulmonologists who may not be familiar with radiosurgery ...
Cached Medicine Technology:PharMEDium Highlights Enhanced Labeling for ICU Services at Critical Care Expo 2Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer 2Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer 3Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer 4
(Date:5/26/2013)... In the five years through 2013, revenue ... been growing at an average annualized rate of 7.7% to ... in poultry prices as well as output growth, says IBISWorld. ... a healthier alternative to other meats. Additionally, poultry meat represents ... than the world average. And although pork is still the ...
(Date:5/25/2013)... Utah (PRWEB) May 25, 2013 Today, ... health insurance marketplaces . Zane Benefits, which provides comprehensive ... is the leader in defined contribution plans ... website, the October 1, 2013 open enrollment of the ... mantra of the Marketplaces is "Choice, Competition and Clout ...
(Date:5/25/2013)... Imagine running the air conditioner with the windows open ... wasted energy! If the home has a folding pull-down attic ... that may be just what is occurring in the home ... energy in the form of higher energy bills. Drafts are ... home. , Drafts occur through the small cracks around doors, ...
(Date:5/25/2013)... Dr. Leslie Gerstman announced today that Ultherapy ... the neck, on the brow and under the chin -- ... is a non-surgical procedure for the face and neck that ... skin over time. The use of FDA-cleared ultrasound technology enables ... the deepest support layers of the skin – typically addressed ...
(Date:5/25/2013)... Communities of Distinction TV announces ... fifth largest media market in the United States with almost ... destination in Texas and a major convention city. Ft. Worth ... as it is home to many major museums. Both cities ... to the arts. Residents and locals will be able to ...
Breaking Medicine News(10 mins):Health News:Poultry Farming Industry in China Industry Research Report – Now Available from IBISWorld 2Health News:Poultry Farming Industry in China Industry Research Report – Now Available from IBISWorld 3Health News:Zane Benefits Publishes New Information on the Health Insurance Marketplaces 2Health News:Zane Benefits Publishes New Information on the Health Insurance Marketplaces 3Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 2Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 3Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 4Health News:Dr. Leslie Gerstman Is Now Offering the Non-surgical Facelifting Procedure – Ultherapy – in NYC and NJ 2Health News:Communities of Distinction TV Presents May Air Dates for Dallas-Ft. Worth, Texas 2
... DALLAS April 19, 2011 A device developed ... of pelvic fractures with minimal postsurgical scarring, pain and ... the nation,s 200 level I trauma centers. ... Reinert developed the Starr Frame, its associated accessories and ...
... , MONDAY, April 18 (HealthDay News) -- Hospitals are ... not have hemophilia, a rare disorder in which blood does ... patients is potentially risky, according to new research. Stanford ... recombinant factor 7a, grew by 140 times from use in ...
... Gardner HealthDay Reporter , MONDAY, April 18 (HealthDay ... suicide when they live in communities where they feel they ... simply because more same-sex couples live in the area, new ... April 18 in Pediatrics , lesbian, gay and bisexual ...
... 18 (HealthDay News) -- Most people with a reduced sense of ... anything at all -- adjust and learn to cope, researchers say. ... less importance on the sense of smell in their daily lives ... included 470 people, half who either lacked or had a reduced ...
... , MONDAY, April 18 (HealthDay News) -- Healthy ... a type of blood fat associated with heart disease ... scientific statement released Monday. About one-third (31 percent) ... levels, defined as more than 150 milligrams per deciliter ...
... list, can reduce problems with recurring low back pain, reveals ... people suffer with low back pain, and most get better. ... their work, everyday and leisure activities are limited to varying ... is important that the pain be treated at an early ...
Cached Medicine News:Health News:Pelvic-repair device developed by UT Southwestern surgeons enables minimally invasive trauma surgery 2Health News:Pelvic-repair device developed by UT Southwestern surgeons enables minimally invasive trauma surgery 3Health News:Off-Label Use of Clotting Drug Soars, Report Finds 2Health News:Support May Help Curb Suicide Among Gay Youths 2Health News:Support May Help Curb Suicide Among Gay Youths 3Health News:Poor Sense of Smell Not a Big Loss for Most People: Study 2Health News:Lifestyle Changes Can Slash Blood Fat Levels, Experts Say 2Health News:Immediate treatment can alleviate future back problems 2
PremierEdge™ Implant Knives....
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
PremierEdge™ Clear Cornea Knives - Trapezoid....
Medicine Products: